Andrew Baum
Stock Analyst at Citigroup
(1.27)
# 1837
Out of 5,352 analysts
49
Total ratings
52.00%
Success rate
13.13%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MRK Merck & Co | Downgrades: Neutral | 115 84 | 77.06 | 9.01% | 10 | May 14, 2025 | |
PFE Pfizer | Maintains: Neutral | 30 29 | 23.36 | 24.14% | 6 | Jan 28, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 60 65 | 48.1 | 35.14% | 9 | Jan 28, 2025 | |
RPRX Royalty Pharma | Maintains: Buy | 60 40 | 33.29 | 20.16% | 2 | Oct 25, 2024 | |
ABBV AbbVie | Maintains: Strong Buy | 170 215 | 187.14 | 14.89% | 11 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 675 895 | 750.81 | 19.2% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 11.44 | -12.59% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |